About Shanghai Micurx Pharmaceutical Company

The company was founded in 2007. It is an innovative biomedical enterprise with global independent intellectual property rights and international competitiveness with the treatment of infectious diseases as the core. It is committed to discovering, developing and commercializing innovative drugs that do not meet clinical needs. Since its inception, the company has always adhered to the concept of “seeking good results through good medicine”, focusing on the increasingly serious problem of bacterial drug resistance around the world, solving clinical problems and differentiated innovation as its core competitiveness, and aiming to provide more effective and safer treatment options for the most common and serious clinically resistant bacterial infections. The company is an innovative drug enterprise with small molecule chemical drug research and development as the core, treatment of infectious diseases as the focus area, and has independent global intellectual property rights and international competitiveness. It is committed to discovering, developing and commercializing innovative drugs that do not meet clinical needs. The main products are MRX-1 contezolamide tablets, MRX-4, MRX-8, and MRX-5.